Healthcare, Digital Health & Life Sciences

Supporting institutional investors and businesses across the healthcare and life sciences sector at all stages of their development - helping them to navigate legal and regulatory risks and seize commercial opportunities.

We support health and social care providers, digital health and life sciences companies and investors and lenders focusing on the sector with their legal and regulatory requirements.

We have the experience and industry insights to help our clients to navigate legal and compliance risks, address workforce and business continuity challenges, manage disputes and pursue new commercial opportunities in this highly regulated sector.

Our clients include many NHS trusts, local authorities, leading independent UK hospital and care home operators, private providers of a wide range of other health and social care services (including charities) and early stage and growth biotech and digital health companies. We also regularly work with private equity, venture capital and other institutional investors with a focus on healthcare, life sciences and the growing digital health space.

Our healthcare & life sciences experience

  • Advising on the sale of Careflow Connect, a developer of a mobile communications system for clinicians and care professionals, to System C Healthcare.
  • Acting for a regional care home group on the acquisition of new homes and advising on legal matters across their care home portfolio.
  • Advising on the sale of Research Instruments, specialising in cutting-edge technology, consumables and hardware in the field of in-vitro fertilisation and in micromanipulation technology, to Cooper Surgical for US$51m.
  • Acting for a US global leader in the distribution of pharmaceutical supplies on the construction and fit out of its UK facility to comply with requirements of the Medicines and Healthcare products Regulatory Agency.
  • Advising Iksuda Therapeutics, a company developing a new generation of antibody drug conjugates which target cancer tumours that currently have limited treatment options and high relapse rates, on its $47m Series A investment round led by Korean investors Mirae Asset and Celltrion.
"The Ashfords team provide complete oversight of complex transactional/licensing negotiations and agreements whilst appreciating the need for clarity and pragmatism."
Legal 500 2024
"The Ashfords team provide exemplary advice and guidance which is stage appropriate and tailored to the company’s requirements."
Legal 500 2024
"Experienced, knowledgeable, pragmatic and professional. Thoroughly well-versed in the sector, at least equal to a prestigious international firm."
Legal 500 2023

Get in touch

We are lawyers you can count on to deliver. If you’d like to find out more about our services and whether we can help you, click the button below and get in touch.

Our team will be responsive and accessible – a valued partner ready to assist you every step of the way.

Contact us
Alt Contact Image

Sign up for legal insights

We produce a range of insights and publications to help keep our clients up-to-date with legal and sector developments.  

Sign up